Does Tricare Cover GLP-1 Medications? A Drug-by-Drug Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Tricare covers GLP-1 medications across both T2D and weight-loss indications, with drug-specific PA criteria
• T2D-indicated drugs (Mounjaro, Ozempic) face simpler PA than weight-loss drugs (Zepbound, Wegovy, Saxenda)
• Active duty service members face additional fitness-for-duty considerations for weight-loss GLP-1s
• The Tricare Mail Order Pharmacy through Express Scripts offers the lowest cost-sharing
• The December 2024 OSA approval of Zepbound created a new covered indication that may apply where weight-loss criteria don't fit

Direct answer

Tricare coverage of GLP-1 medications varies by drug and indication. T2D-indicated medications (Mounjaro, Ozempic) are covered with standard prior authorization requiring T2D diagnosis, A1C documentation, and metformin trial. Weight-loss-indicated medications (Zepbound, Wegovy, Saxenda) are also covered with stricter PA requiring BMI ≥ 30 (or BMI ≥ 27 with comorbidity), documented 6-month lifestyle intervention, and prescriber attestation. As of May 2026, confirm current status with the Tricare Formulary Search. The Tricare pharmacy benefit is administered by Express Scripts. Active duty service members pay $0 for covered medications; dependents and retirees pay tiered copays. The December 2024 FDA approval of Zepbound for obstructive sleep apnea created an additional covered indication that may apply for patients who don't meet weight-loss criteria.

Table of contents

1. How Tricare pharmacy benefits work
2. Drug-by-drug coverage summary
3. Mounjaro and Ozempic for T2D
4. Zepbound and Wegovy for weight loss
5. The OSA indication after December 2024
6. Active duty fitness-for-duty considerations
7. Costs by Tricare plan and pharmacy type
8. Dependents and retirees
9. The Tricare appeal process
10. FAQ
11. Sources

How Tricare pharmacy benefits work

Tricare is the health benefits program for uniformed service members, retirees, and their families. The pharmacy benefit is administered by Express Scripts under federal contract. Prescriptions can be filled through:

• Military pharmacy: Lowest cost (often $0); limited formulary
• Tricare Mail Order Pharmacy (TMOP): Lower copays; 90-day supply; ships from Express Scripts
• Retail network pharmacy: Higher per-fill cost; immediate availability
• Non-network pharmacy: Highest cost; partial reimbursement

The Tricare formulary lists covered drugs with tier placement and PA requirements. Express Scripts administers PAs through its clinical review process.

Drug-by-drug coverage summary

Medication	FDA indication	Tricare coverage	PA required?
Mounjaro	Type 2 diabetes	Covered, Tier 3	Yes, T2D PA
Ozempic	Type 2 diabetes	Covered, Tier 3	Yes, T2D PA
Trulicity	Type 2 diabetes	Covered, Tier 3	Yes, T2D PA
Zepbound	Weight loss + OSA	Covered, Tier 3	Yes, AOM or OSA PA
Wegovy	Weight loss	Covered, Tier 3	Yes, AOM PA
Saxenda	Weight loss	Covered, Tier 3	Yes, AOM PA

All GLP-1 medications on the Tricare formulary require PA. The criteria differ between T2D indications and weight-loss indications.

Mounjaro and Ozempic for T2D

For T2D-indicated GLP-1 medications, Tricare PA requirements:

• Documented type 2 diabetes diagnosis (ICD-10 E11)
• Recent A1C measurement (within 90 days), generally ≥ 7.0%
• Trial of metformin at maximum tolerated dose (unless contraindicated)
• Some scenarios: trial of one additional oral T2D agent
• Prescriber attestation of continued diet/exercise counseling
• No concurrent GLP-1 use

T2D PAs are processed through Express Scripts with standard 24-72 hour turnaround. Active duty members have priority processing for medications affecting deployment readiness.

Zepbound and Wegovy for weight loss

For weight-loss-indicated GLP-1 medications, Tricare PA is stricter:

• BMI ≥ 30, or BMI ≥ 27 with at least one obesity-related comorbidity
• Documented 6-month comprehensive lifestyle intervention prior to PA submission
• Age ≥ 18 (separate adolescent criteria for Saxenda when applicable)
• Prescriber attestation of continued behavioral/dietary intervention
• No concurrent GLP-1 use
• Reauthorization at 6 months: ≥ 5% baseline weight loss documented

For active duty members, weight-loss PAs include additional review for fitness-for-duty implications.

The OSA indication after December 2024

The FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024) opened a new covered indication on Tricare. The OSA pathway has been added to Tricare formulary criteria during 2025.

OSA pathway requirements:

• Polysomnography or home sleep apnea test showing AHI ≥ 15 events/hour
• BMI ≥ 30
• ICD-10 G47.33 on the prescription and PA
• Trial of CPAP or documented contraindication

For active duty members and Reserve/National Guard with OSA, the OSA indication can be particularly relevant because OSA is a recognized medical condition with operational implications. Coverage under the OSA indication is more straightforward than under weight-loss criteria for service members with operational fitness considerations.

Active duty fitness-for-duty considerations

Tricare-covered medications for active duty members face additional review beyond standard PA:

• Medications affecting weight, energy, GI function, or operational readiness require clinical clearance
• GLP-1 side effects (nausea, fatigue) may be incompatible with certain operational duties or deployments
• The Department of Defense has issued guidance on GLP-1 use in service members; consult your military medical provider
• Deployment medical screening may identify GLP-1 use that requires medical waiver or discontinuation

The clinical decision for active duty members involves both standard medical considerations and operational fitness review. The OSA indication can simplify this when applicable because OSA treatment is a recognized medical priority for service members.

Costs by Tricare plan and pharmacy type

2026 Tricare pharmacy cost-sharing for non-active-duty members:

Pharmacy type	Generic	Formulary brand	Non-formulary brand
Military pharmacy (in-store)	$0	$0	Not covered
TMOP mail order (90-day supply)	$13	$33	$74
Retail network (30-day supply)	$15	$33	$66
Non-network pharmacy	50% after deductible	50% after deductible	50% after deductible

GLP-1 medications (Mounjaro, Ozempic, Zepbound, Wegovy) are formulary brand: $33 per 90-day supply through TMOP or $33 per 30-day supply through retail network for Tricare Prime/Select members. Active duty pay $0.

Dependents and retirees

Dependents (spouses, children) and military retirees receive the same Tricare pharmacy benefit as non-active-duty members with the cost-sharing shown above. PA requirements are identical.

For retirees and Tricare for Life (Medicare-eligible) members:

• Tricare for Life acts as secondary coverage to Medicare
• Medicare Part D rules apply for prescription coverage (Medicare's weight-loss exclusion applies to retirees with Medicare eligibility)
• Mounjaro for T2D is covered through Part D + Tricare for Life secondary
• Zepbound for weight loss is generally not covered for Medicare-eligible retirees; OSA indication may apply

The Tricare appeal process

Tricare prescription appeals process:

1. Coverage exception request through Express Scripts. Submit within 90 days of denial for retail or 30 days for mail-order. Decision within Tricare-mandated timeframes.
2. Formal appeal through Tricare regional contractor. Available if exception denied. Decision within 60 days.
3. Reconsideration by Defense Health Agency. Final administrative level.
4. Federal court review. Available after administrative exhaustion.

Strong appeals include BMI history, A1C if applicable, ICD-10 diagnosis codes, documented prior interventions, and a prescriber letter of medical necessity. For service members, include fitness-for-duty considerations or operational readiness implications when relevant.

Contrary view: Tricare GLP-1 coverage isn't unrestricted

Tricare offers broader GLP-1 coverage than Medicare (which excludes weight-loss agents entirely) but applies real restrictions:

• Strict BMI and lifestyle-intervention requirements for AOM PA
• Fitness-for-duty considerations limiting active duty access during operational periods
• Tier 3 placement increases cost-sharing relative to lower tiers
• Quantity limits per fill
• Non-coverage of compounded tirzepatide and semaglutide

The Department of Defense has cost concerns about GLP-1 expansion similar to civilian payers. The 2025 DHA pharmacy spend analysis flagged GLP-1 medications as one of the fastest-growing categories. Tricare's PA structure attempts to balance access with cost containment.

For service members with significant T2D or obesity, the access is real and the cost-sharing is reasonable compared to civilian commercial plans. The PA friction is meaningful but generally surmountable with proper documentation.

Decision framework

If you have Tricare and T2D: Mounjaro or Ozempic with T2D PA. Submit complete documentation: T2D diagnosis, A1C, metformin trial.

If you have Tricare and meet weight-loss BMI: Zepbound or Wegovy with AOM PA. Document 6-month lifestyle intervention.

If you have Tricare and OSA: Zepbound under OSA pathway. Sleep study required.

If you're active duty: Include fitness-for-duty review with your military medical provider.

If you're Tricare for Life: Medicare rules govern. Mounjaro for T2D covered; Zepbound for weight loss excluded.

FAQ

Does Tricare cover GLP-1 medications? Yes for all major branded GLP-1s. PA criteria differ between T2D and weight-loss indications.

Does Tricare cover Mounjaro? Yes for T2D with PA.

Does Tricare cover Zepbound? Yes for weight loss with strict PA, and for OSA after December 2024 approval.

Does Tricare cover Wegovy? Yes for weight loss with strict PA.

Does Tricare cover Ozempic? Yes for T2D with PA.

What does it cost? $0 for active duty; $33 per 90-day TMOP fill or 30-day retail fill for formulary brand Tier for non-active-duty.

How do I appeal a denial? Coverage exception through Express Scripts; formal appeal through Tricare regional contractor; DHA reconsideration.

Does Tricare cover compounded tirzepatide? No. Compounded medications are not FDA-approved.

Sources

1. FDA. Mounjaro, Zepbound, Ozempic, Wegovy prescribing information. Updated 2024.
2. Jastreboff AM et al. Tirzepatide Once Weekly for Treatment of Obesity. NEJM. 2022.
3. Frias JP et al. Tirzepatide versus Semaglutide in T2D (SURPASS-2). NEJM. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021.
5. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity. NEJM. 2024.
6. Defense Health Agency. Tricare Formulary. Accessed May 2026.
7. Tricare Pharmacy Program. Cost-sharing schedule. 2026.
8. Express Scripts. Tricare clinical formulary management. 2026.
9. Department of Defense. Health-readiness guidance on weight-management medications. 2024-2025.
10. American Diabetes Association. Standards of Care in Diabetes 2026.
11. CMS. Medicare Part D and Tricare for Life coordination of benefits. Updated 2025.
12. The Obesity Society. Military medicine and obesity treatment access. 2024 position statement.

Footer disclaimers

Platform Disclaimer. FormBlends offers educational information about Tricare and other insurance coverage policies. We are not a Tricare contractor, a Defense Health Agency representative, or an authorized military medical advisor. For service-specific coverage questions, consult your military medical provider or the Tricare Beneficiary Counseling and Assistance Coordinator (BCAC) at your installation.

Compounded Medication Notice. Compounded tirzepatide and semaglutide are prepared by state-licensed 503A pharmacies under valid individual prescriptions. They are not FDA-approved and are not therapeutically interchangeable with branded products. Tricare does not cover compounded medications on its formulary.

Results Disclaimer. The coverage examples, PA criteria, cost figures, and operational considerations in this article reflect publicly available Tricare and Defense Health Agency documentation as of writing. Tricare policies and DHA guidance update periodically. Verify current rules with the Tricare Formulary Search and your military medical provider.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk. Tricare is a registered trademark of the U.S. Department of Defense. Express Scripts is a registered trademark of The Cigna Group. FormBlends has no affiliation with the Department of Defense, the Defense Health Agency, Tricare, or any pharmaceutical manufacturer referenced.